Scheen AJ A review of gliptins for 2014. Exp Opin Pharmacother 2015, 16:43-62.
Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol 2015, published online Jan 19. http://dx.doi.org/10.1016/S2213-8587(14)70251-7.
Scheen AJ, Paquot N Gliptin versus a sulphonylurea as add-on to metformin. Lancet 2012, 380:450-452.
Craddy P, Palin HJ, Johnson KI Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther 2014, 5:1-41.
Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010, 26:540-549.
Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther 2013, 4:431-442.
Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 2014, 57:3205-3212.
Gantz I, Okamoto T, Ito Y, Okuyama K, Engel SS Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial (abstract). Diabetologia 2014, 57(suppl 1):S55.
Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013, 56:696-708.
Scheen AJ Which incretin-based therapy for type 2 diabetes?. Lancet 2014, 384:1325-1357.
